
Size-exclusion chromatography (SEC) was used to purify extracellular vesicles (EVs) from the plasma of chronic myeloid leukemia (CML) patients to evaluate treatment responses and mutation statuses. This study demonstrates that precisely isolating EVs using chromatography allows for deep proteomic analysis, which can provide valuable insights into a patient's clinical status and reveal potential biomarkers for monitoring CML treatment response, remission, and drug resistance.




























